[开放获取]  小分子靶向药物：银屑病治疗的新选择

doi:10.35541/cjd.20210630

中华皮肤科杂志 ›› 2022, Vol. 55 ›› Issue (9): 747-751.doi: 10.35541/cjd.20210630

[开放获取] 小分子靶向药物：银屑病治疗的新选择

俞晨王刚

第四军医大学西京皮肤医院，西安 710032

收稿日期:2021-08-27 修回日期:2022-05-07 发布日期:2022-09-02
通讯作者: 王刚 E-mail:xjwgang@fmmu.edu.cn

Small-molecule targeted agents: new choices for the treatment of psoriasis

Yu Chen, Wang Gang

Department of Dermatology, Xijing Hospital, The Fourth Military Medical University, Xi′an 710032, China

Received:2021-08-27 Revised:2022-05-07 Published:2022-09-02
Contact: WANG Gang E-mail:xjwgang@fmmu.edu.cn

摘要/Abstract

摘要： 【摘要】随着免疫学和分子生物学的飞速发展，银屑病发病机制研究取得了显著的进步，靶向发病机制中关键分子的治疗策略也取得了很大的成功。除生物制剂外，银屑病小分子靶向药物日益受到关注，以磷酸二酯酶4、Janus激酶、酪氨酸激酶2等为主要靶分子，越来越多的候选药物在研究中观察到较好的疗效，部分药物已获批用于临床，在银屑病的治疗中发挥独特的作用。

关键词: 银屑病, 磷酸二酯酶4抑制剂, Janus激酶抑制剂, 酪氨酸激酶2抑制剂, 小分子药物

Abstract: 【Abstract】 With the rapid development of immunology and molecular biology in recent years, great progress has been made in the research on psoriatic pathogenesis, as well as in therapeutic strategies targeting key molecules in the pathogenesis. In addition to biologics, small-molecule targeted agents for psoriasis have also received increasing attention, especially agents targeting phosphodiesterase 4, Janus kinase, and tyrosine kinase 2, etc. An increasing number of small-molecule drug candidates have shown favorable efficacy in clinical studies, and some of them have been approved for clinical application and play a unique role in the treatment of psoriasis.

Key words: Psoriasis, Phosphodiesterase 4 inhibitors, Janus kinase inhibitors, Tyrosine kinase 2 inhibitors, Small molecules

俞晨王刚. [开放获取] 小分子靶向药物：银屑病治疗的新选择[J]. 中华皮肤科杂志, 2022,55(9):747-751. doi:10.35541/cjd.20210630

Yu Chen, Wang Gang. Small-molecule targeted agents: new choices for the treatment of psoriasis[J]. Chinese Journal of Dermatology, 2022, 55(9): 747-751.doi:10.35541/cjd.20210630

参考文献 32

［1］	Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review［J］. JAMA, 2020,323（19）:1945⁃1960. doi: 10.1001/jama.2020.4006.
［2］	Honma M, Hayashi K. Psoriasis: recent progress in molecular⁃targeted therapies［J］. J Dermatol, 2021,48（6）:761⁃777. doi:10. 1111/1346⁃8138.15727.
［3］	Ghoreschi K, Balato A, Enerbäck C, et al. Therapeutics targeting the IL⁃23 and IL⁃17 pathway in psoriasis［J］. Lancet, 2021,397（10275）:754⁃766. doi: 10.1016/S0140⁃6736（21）00184⁃7.
［4］	Balogh EA, Bashyam AM, Ghamrawi RI, et al. Emerging systemic drugs in the treatment of plaque psoriasis［J］. Expert Opin Emerg Drugs, 2020,25（2）:89⁃100. doi: 10.1080/14728214. 2020.1745773.
［5］	Grand D, Navrazhina K, Frew JW, et al. Research pipeline I: oral therapeutics for psoriasis//Weinberg JM, Lebwohl M. Advances in psoriasis: a multisystemic guide［M］. Cham, Switzerland:Springer, 2021:291⁃302. doi: 10.1007/978⁃3⁃030⁃54859⁃9_23.
［6］	Weisel K, Scott NE, Tompson DJ, et al. Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers［J］. Pharmacol Res Perspect, 2017,5（6）:e00365. doi: 10.1002/prp2.365.
［7］	Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 （PDE4） inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial （Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis ［ESTEEM］ 1）［J］. J Am Acad Dermatol, 2015,73（1）:37⁃49. doi: 10.1016/j.jaad.2015.03.049.
［8］	Reich K, Gooderham M, Green L, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate⁃to⁃severe plaque psoriasis: 52⁃week results from a phase IIIb, randomized, placebo⁃controlled trial （LIBERATE）［J］. J Eur Acad Dermatol Venereol, 2017,31（3）:507⁃517. doi: 10.1111/jdv. 14015.
［9］	Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate⁃to⁃severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial （ESTEEM 2）［J］. Br J Dermatol, 2015,173（6）:1387⁃1399. doi: 10.1111/bjd.14164.
［10］	Lebwohl MG, Papp KA, Stein Gold L, et al. Trial of roflumilast cream for chronic plaque psoriasis［J］. N Engl J Med, 2020,383（3）:229⁃239. doi: 10.1056/NEJMoa2000073.
［11］	Kvist⁃Hansen A, Hansen PR, Skov L. Systemic treatment of psoriasis with JAK inhibitors: a review［J］. Dermatol Ther （Heidelb）, 2020,10（1）:29⁃42. doi: 10.1007/s13555⁃019⁃00347⁃w.
［12］	Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo⁃controlled, phase III trials［J］. Br J Dermatol, 2015,173（4）:949⁃961. doi: 10.1111/bjd. 14018.
［13］	Zhang J, Tsai TF, Lee MG, et al. The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: a phase 3, randomized, double⁃blind, placebo⁃controlled study［J］. J Dermatol Sci, 2017,88（1）:36⁃45. doi: 10. 1016/j.jdermsci.2017.05.004.
［14］	Bachelez H, van de Kerkhof PC, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate⁃to⁃severe chronic plaque psoriasis: a phase 3 randomised non⁃inferiority trial［J］. The Lancet, 2015, 386（9993）:552⁃561. doi: 10.1016/S0140⁃6736（14）62113⁃9.
［15］	Krueger JG, McInnes IB, Blauvelt A. Tyrosine kinase 2 and Janus kinase⁃signal transducer and activator of transcription signaling and inhibition in plaque psoriasis［J］. J Am Acad Dermatol, 2022,86（1）:148⁃157. doi: 10.1016/j.jaad.2021.06.869.
［16］	McInnes IB, Anderson JK, Magrey M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis［J］. N Engl J Med, 2021,384（13）:1227⁃1239. doi: 10.1056/NEJMoa2022516.
［17］	Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT⁃PsA 2［J］. Ann Rheum Dis, 2020,80（3）:312⁃320. doi: 10.1136/annrheumdis⁃2020⁃218870.
［18］	Papp K, Gordon K, Thaçi D, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis［J］. N Engl J Med, 2018,379（14）:1313⁃1321. doi: 10.1056/NEJMoa1806382.
［19］	Wrobleski ST, Moslin R, Lin S, et al. Highly selective inhibition of tyrosine kinase 2 （TYK2） for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS⁃986165［J］. J Med Chem, 2019,62（20）:8973⁃8995. doi: 10.1021/acs.jmedchem. 9b00444.
［20］	Enerbäck C, Sandin C, Lambert S, et al. The psoriasis⁃protective TYK2 I684S variant impairs IL⁃12 stimulated pSTAT4 response in skin⁃homing CD4+ and CD8+ memory T⁃cells［J］. Sci Rep, 2018,8（1）:7043. doi: 10.1038/s41598⁃018⁃25282⁃2.
［21］	Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain［J］. Sci Transl Med, 2019,11（502）:eaaw1736. doi: 10.1126/scitranslmed.aaw1736.
［22］	Armstrong A, Gooderham M, Warren RB, et al. Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 （TYK2） inhibitor, compared with placebo and apremilast in moderate to severe plaque psoriasis: results from the phase 3 POETYK PSO⁃1 study［J］. Ann Rheum Dis,2021, 80（Suppl 1）:795⁃796. doi: 10.1136/annrheumdis⁃2021⁃eular.1002.
［23］	Gerstenberger BS, Ambler C, Arnold EP, et al. Discovery of tyrosine kinase 2 （TYK2） inhibitor （PF⁃06826647） for the treatment of autoimmune diseases［J］. J Med Chem, 2020,63（22）:13561⁃13577. doi: 10.1021/acs.jmedchem.0c00948.
［24］	Fensome A, Ambler CM, Arnold E, et al. Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of （（S）⁃2,2⁃Difluorocyclopropyl）（（1 R,5 S）⁃3⁃（2⁃（（1⁃methyl⁃1 H⁃pyrazol⁃4⁃yl）amino）pyrimidin⁃4⁃yl）⁃3,8⁃diazabicyclo［3.2.1］octan⁃8⁃yl）methanone （PF⁃06700841）［J］. J Med Chem, 2018,61（19）:8597⁃8612. doi: 10.1021/acs.jmedchem. 8b00917.
［25］	Forman SB, Pariser DM, Poulin Y, et al. TYK2/JAK1 inhibitor PF⁃06700841 in patients with plaque psoriasis: phase IIa, randomized, double⁃blind, placebo⁃controlled trial［J］. J Invest Dermatol, 2020,140（12）:2359⁃2370.e5. doi: 10.1016/j.jid.2020. 03.962.
［26］	Vaclavkova A, Chimenti S, Arenberger P, et al. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double⁃blind, placebo⁃controlled phase 2 trial［J］. The Lancet, 2014, 384（9959）:2036⁃2045. doi: 10.1016/s0140⁃6736（14）60803⁃5.
［27］	Weisel K, Berger S, Papp K, et al. Response to inhibition of receptor⁃interacting protein kinase 1 （RIPK1） in active plaque psoriasis: a randomized placebo⁃controlled study［J］. Clin Pharmacol Ther, 2020,108（4）:808⁃816. doi: 10.1002/cpt.1852.
［28］	Cores Á, Piquero M, Villacampa M, et al. NRF2 regulation processes as a source of potential drug targets against neurodegenerative diseases［J］. Biomolecules, 2020,10（6）:904.doi: 10.3390/biom10060904.
［29］	Gao W, Guo L, Yang Y, et al. Dissecting the crosstalk between Nrf2 and NF⁃κB response pathways in drug⁃induced toxicity［J］. Front Cell Dev Biol, 2021,9:809952. doi: 10.3389/fcell.2021. 809952.
［30］	Swindell WR, Bojanowski K, Chaudhuri RK. Transcriptomic analysis of fumarate compounds identifies unique effects of isosorbide di⁃（methyl fumarate） on NRF2, NF⁃kappaB and IRF1 pathway genes［J］. Pharmaceuticals, 2022,15（4）:461. doi:10.3390/ph15040461.
［31］	Mrowietz U, Szepietowski JC, Loewe R, et al. Efficacy and safety of LAS41008 （dimethyl fumarate） in adults with moderate⁃to⁃severe chronic plaque psoriasis: a randomized, double⁃blind, Fumaderm®⁃and placebo⁃controlled trial （BRIDGE）［J］. Br J Dermatol, 2017,176（3）:615⁃623. doi: 10.1111/bjd.14947.
［32］	Cai L, Chen GH, Lu QJ, et al. A double⁃blind, randomized, placebo⁃ and positive⁃controlled phase III trial of 1% benvitimod cream in mild⁃to⁃moderate plaque psoriasis［J］. Chin Med J （Engl）, 2020,133（24）:2905⁃2909. doi: 10.1097/CM9. 0000000000001221.

[1]	肖春英王刚. 朗格汉斯细胞在银屑病中的作用研究进展[J]. 中华皮肤科杂志, 2022, 55(9): 830-834.
[2]	周雪, 余增洋, 陈有东, 郭春源, 于倩, 胡艺凡, 姚玲玲, 史玉玲, . 肿瘤坏死因子α介导银屑病脂肪酸去饱和酶2低表达[J]. 中华皮肤科杂志, 2022, 55(9): 752-758.
[3]	姚玲玲, 余增洋郭春源周静崔莲于倩虞英媛周雪蔡江鲁伊史玉玲, . 节律基因隐花色素2在银屑病小鼠模型及HaCaT细胞中的表达变化及机制研究[J]. 中华皮肤科杂志, 2022, 55(9): 759-766.
[4]	孙杰王睿李承新. 肿瘤坏死因子α抑制剂诱导的银屑病研究进展[J]. 中华皮肤科杂志, 2022, 55(9): 821-824.
[5]	刘晋沈征宇. 银屑病表观遗传调控的研究进展[J]. 中华皮肤科杂志, 2022, 55(9): 825-829.
[6]	郑佳媛余炳前陈显侠骆志成. 成人寻常型银屑病瘙痒特征及对生活质量的影响调查[J]. 中华皮肤科杂志, 2022, 55(9): 790-794.
[7]	王玲艳潘靖苗钢常晓丹金秋子郭宁宁张佳钰. 对生物制剂治疗抵抗的银屑病患者皮损部位分析[J]. 中华皮肤科杂志, 2022, 55(7): 583-587.
[8]	中国医师协会皮肤科医师分会自身免疫病专业委员会 . 【开放获取】环孢素治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2022, 55(6): 471-479.
[9]	闪莹左亚刚. 自身免疫性疱病与银屑病的相关性[J]. 中华皮肤科杂志, 2022, 55(5): 452-455.
[10]	中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组中华医学会皮肤性病学分会儿童学组中国老年保健医学研究会皮肤科分会. 特应性皮炎外用制剂合理应用及患者指导专家共识[J]. 中华皮肤科杂志, 2022, 55(4): 281-288.
[11]	王召阳陈安薇向欣罗晓燕徐子刚王华马琳. 基于两家儿童医院信息系统的儿童银屑病现状调查[J]. 中华皮肤科杂志, 2022, 55(3): 246-250.
[12]	《脓疱型银屑病诊疗中国专家共识（版）》编写委员会专家组. 脓疱型银屑病诊疗中国专家共识（2022版）[J]. 中华皮肤科杂志, 2022, 55(3): 187-195.
[13]	王晓雯李若瑜. 白细胞介素17相关生物制剂治疗银屑病过程中浅部真菌感染的发生及应对策略[J]. 中华皮肤科杂志, 2022, 55(3): 272-275.
[14]	王玥严煜林. 寻常型银屑病患者171例阿维A治疗相关不良反应及停药原因分析[J]. 中华皮肤科杂志, 2022, 55(3): 242-245.
[15]	李妍李明徐薇李邻峰. 【开放获取】丙酸氟替卡松乳膏单独或联合卡泊三醇软膏治疗轻中度斑块状银屑病的随机自身对照研究[J]. 中华皮肤科杂志, 2022, 55(3): 260-263.

[开放获取] 小分子靶向药物：银屑病治疗的新选择

Small-molecule targeted agents: new choices for the treatment of psoriasis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 32

相关文章 15

Metrics

本文评价

推荐阅读 10